Protective action of tetramethylpyrazine phosphate against dilated cardiomyopathy in cTnTR141W transgenic mice

Acta Pharmacologica Sinica

Volumn 31, Issue 3, 2010, Pages 281-288

  Zhao, Hai Ping ^a   Lü, Dan ^a   Zhang, Wei ^a   Zhang, Li ^a   Wang, Shu Mei ^a   Ma, Chun Mei ^b   Qin, Chuan ^b   Zhang, Lian Feng ^a  

^a BEIJING HOSPITAL   (China)

^b INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

CTnTR141W transgenic mouse; Dilated cardiomyopathy; Survival; Tetramethylpyrazine phosphate

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALM1 PROTEIN; CAMK2B PROTEIN; COL1A1 PROTEIN; COL3A1 PROTEIN; INTERSTITIAL COLLAGENASE; MOLECULAR MARKER; PROTEIN DERIVATIVE; PYRAZINE DERIVATIVE; TETRAMETHYLPYRAZINE; TETRAMETHYLPYRAZINE PHOSPHATE; UNCLASSIFIED DRUG; UVOMORULIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; HEART; HEART DILATATION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMERE; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CADHERINS; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; HEART; HUMANS; HYPERTROPHY; LIGUSTICUM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE PROTEINS; MUTATION; MYOCARDIUM; PLATELET AGGREGATION INHIBITORS; PYRAZINES; TROPONIN T;

EID: 77749251951     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.6     Document Type: Article

References (34)

1. Richardson P, Mckenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 world health organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-2.
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006; 113: 1807-16.
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18.
4. Kamisago M, Sharma SD, Depalma SR, Solomon S, Sharma P, Mc-Donough B, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343: 1688-96.
5. Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998; 10: 131-9.
6. Li D, Czernuszewicz GZ, Gonzalez O, Tapscott T, Karibe A, Durand JB, et al. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 2001; 104: 2188-93.
7. R141W transgenic mice. Int J Cardiol 2008; 128: 83-90.
8. 2+ channel? J Cardiovasc Pharmacol 1990; 15: 157-62.
9. Sheu JR, Kan YC, Hung WC, Lin CH, Yen MH. The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase. Life Sci 2000; 67: 937-47.
10. Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sci 2003; 72: 2465-72.
11. Pang PK, Shan JJ, Chiu KW. Tetramethylpyrazine, a calcium antagonist. Planta Med 1996; 62: 431-5.
12. 2+ transients in isolated adult rat ventricular myocytes. Vasc Pharmacol 2003; 40: 213-7.
13. Chen KJ, Chen K. Ischemic stroke treated with Ligusticum chuanxiong. Chin Med J 1992; 105: 870-3.
14. Sutter MC, Wang YX. Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res 1993; 27: 1891-901.
15. Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemo-dialysis patients. Kidney International 2005; 67: 333-40.
16. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995; 27: 291-305.
17. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Circulation 1995; 92: 2306-17.
18. Branishte TA, Dudnakova TV, Dergilev KV, Severin VV, Naumov VG, Shirinskiǐ VP, et al. Expression of contractile and cytoskeletal proteins in myocardium of patients with dilated cardiomyopathy. Kardiologiia 2004; 44: 31-6.
19. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997; 88: 393-403.
20. Hayashi T, Arimura T, Itoh-Satoh M, Ueda K, Hohda S, Inagaki N, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44: 2192-201.
21. Duboscq-Bidot L, Xu P, Charron P, Neyroud N, Dilanian G, Millaire A, et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc Res 2008; 77: 118-25.
22. Kostetskii I, Li J, Xiong Y, Zhou R, Ferrari VA, Patel VV, et al. Induced deletion of the N-cadherin gene in the heart leads to dissolution of the intercalated disc structure. Circ Res 2005; 96: 346-54.
23. Salmikangas P, van der Ven PF, Lalowski M, Taivainen A, Zhao F, Suila H, et al. Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum Mol Genet 2003; 12: 189-203.
24. Zeller R, Ivandic BT, Ehlermann P, Mucke O, Zugck C, Remppis A, et al. Large-scale mutation screening in patients with dilated or hypertrophic cardiomyopathy: a pilot study using DGGE. J Mol Med 2006; 84: 682-91.
25. Hauser MA, Horrigan SK, Salmikangas P, Torian UM, Viles KD, Dancel R, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000; 9: 2141-7.
26. Hauser MA, Conde CB, Kowaljow V, Zeppa G, Taratuto AL, Torian UM, et al. Myotilin mutation found in second pedigree with LGMD1A. Am J Hum Genet 2002; 71: 1428-82.
27. Garvey SM, Liu Y, Miller SE, Hauser MA. Myotilin overexpression enhances myopathology in the LGMD1A mouse model. Muscle Nerve 2008; 37: 663-7.
28. Moza M, Mologni L, Trokovic R, Faulkner G, Partanen J, Carpén O. Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice. Mol Cell Biol 2007; 27: 244-52.
29. Perriard JC, Hirschy A, Ehler E. Dilated cardiomyopathy: a disease of the intercalated disc? Trends Cardiovasc Med 2003; 13: 30-8.
30. Ehler E, Horowits R, Zuppinger C, Price RL, Perriard E, Leu M, et al. Alterations at the intercalated disk associated with the absence of muscle LIM protein. J Cell Biol 2001; 153: 763-72.
31. Ferreira-Cornwell MC, Luo Y, Narula N, Lenox JM, Lieberman M, Radice GL. Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart. J Cell Sci 2002; 115: 1623-34.
32. 2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 2004; 63: 476-86.
33. 2+ release. Circ Res 2003; 92: 904-11.
34. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005; 11: 409-17.